BioVoice eMagazine November 2025 | Issue 10 | Volume 6

Click to Read: November 2025 Edition of BioVoice eMagazine

♦ COVER STORY

The Economics of Empathy

A Decade of CSR by India’s Biopharma Industry

In the mid-2010s, corporate social responsibility (CSR) in India settled into an awkward adolescence. The Companies Act (2013) had made CSR spending mandatory for large companies, and the law’s aftershocks were still being felt across industries. For healthcare and biotech firms — producers of medicines, vaccines and health technologies — CSR was more than regulatory compliance: it was an opportunity to translate technical expertise and supply-chain scale into public health interventions. Between 2015 and 2025, CSR in Indian healthcare and biotech matured from a mix of philanthropic ad-hocism to strategic, measurable programs that leaned on partnerships with government, civil society and academic institutions.

This story follows that arc: why healthcare and biotech companies chose certain CSR priorities, how a handful of major players implemented projects that scaled beyond local communities, and what the decade taught the sector about impact, trust and sustainability.

♦ INTERVIEW

“Merck has made significant efforts to strengthen lab solutions and R&D infrastructure in India”

Dhananjay Singh, Managing Director, Merck Life Science & Head of Science & Lab Solutions Commercial shares insights on the company’s latest offerings, technology trends, investment plans and upcoming initiatives.

♦ INTERVIEW

“We plan to invest Rs 50 crore for R&D acceleration, AI integration, and immersive learning ecosystems”

Anuj Chahal, Founder & CEO, Maverick Simulation Solutions, shares insights on the company’s innovation and scaling up strategy, upcoming initiatives and future outlook.

Click to Read: November 2025 Edition of BioVoice eMagazine